Compare Heron Therapeutics Inc (HRTX) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs iShares Core S&P 500 ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while iShares Core S&P 500 ETF trades at $780.42 (market cap $897.20B). The key difference: iShares Core S&P 500 ETF is far larger — about 13192.2× Heron Therapeutics Inc's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and iShares Core S&P 500 ETF for 46 Days on average.
| HRTX | IVV | |
|---|---|---|
Market Cap | $68.01M | $897.20B |
Volume | 1,891,941 | 4,580,672 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.49 | $782.58 |
52-Week Low | $0.27 | $634.93 |
Typical Hold Time | 35 Days | 46 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
IVV, tracking the S&P 500, trades at $780.6, down 0.25% on the day. Technical indicators show a bullish trend with strong moving average support, though RSI suggests potential overbought conditions near-term. The ETF benefits from diversified exposure to large-cap US equities, with recent news highlighting strong corporate earnings growth expectations of 35% for 2026. Market sentiment remains mixed amid concerns about valuation and profit growth normalization.
Outlook remains cautiously optimistic given the S&P 500's historical bullish seasonal patterns and strong institutional support. Key risks include elevated Treasury yields, concentration in top holdings, and potential earnings growth deceleration to 15% in 2027. The ETF's low-cost structure and broad market exposure provide defensive characteristics during market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
